Shell Companies
Build Your Comparison
Side-by-side financial analysisStock Comparison
GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO
Revenue, margins, valuation, and 5-year total return — side by side.
Insurance - Property & Casualty
Insurance - Property & Casualty
Information Technology Services
Drug Manufacturers - Specialty & Generic
Banks - Diversified
Beverages - Non-Alcoholic
GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | |||||||
|---|---|---|---|---|---|---|---|
| Industry | Shell Companies | Insurance - Property & Casualty | Insurance - Property & Casualty | Information Technology Services | Drug Manufacturers - Specialty & Generic | Banks - Diversified | Beverages - Non-Alcoholic |
| Market Cap | $390M | $505M | $2.08B | $367M | $2M | $896.00B | $355.61B |
| Revenue (TTM) | $0.00 | $335M | $927M | $1.74B | $41M | $280.33B | $49.28B |
| Net Income (TTM) | $12M | $107M | $303M | $-199M | $-12M | $57.05B | $13.70B |
| Gross Margin | — | 63.8% | 66.5% | 48.4% | 30.3% | 60.0% | 61.7% |
| Operating Margin | — | 42.6% | 47.9% | 5.5% | -26.7% | 25.9% | 29.3% |
| Forward P/E | 26.4x | 10.9x | 9.3x | 3.3x | — | 14.4x | 25.3x |
| Total Debt | $400K | $152M | $68M | $2.66B | $9M | $942.38B | $45.49B |
| Cash & Equiv. | $113K | $199M | $1.21B | $1.35B | $34M | $343.34B | $10.27B |
GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
| Stock | Jul 24 | Jun 26 | Return |
|---|---|---|---|
| GP-Act III Acquisit… (GPAT) | 100 | 108.2 | +8.2% |
| American Coastal In… (ACIC) | 100 | 85.6 | -14.4% |
| HCI Group, Inc. (HCI) | 100 | 170.2 | +70.2% |
| Paysafe Limited (PSFE) | 100 | 33.8 | -66.2% |
| Universe Pharmaceut… (UPC) | 100 | 0.1 | -99.9% |
| JPMorgan Chase & Co. (JPM) | 100 | 150.7 | +50.7% |
| The Coca-Cola Compa… (KO) | 100 | 123.8 | +23.8% |
Price return only. Dividends and distributions are not included.
Quick Verdict: GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO
Each card shows where this stock fits in a portfolio — not just who wins on paper.
GPAT is the clearest fit if your priority is bank quality.
- NIM 4.0% vs JPM's 2.2%
ACIC ranks third and is worth considering specifically for stability.
- Beta 0.10 vs PSFE's 2.44, lower leverage
HCI has the current edge in this matchup, primarily because of its strength in growth exposure and sleep-well-at-night.
- Rev growth 20.2%, EPS growth 179.8%, 3Y rev CAGR 22.3%
- Lower volatility, beta 0.36, Low D/E 6.1%, current ratio 1.24x
- PEG 0.19 vs KO's 2.26
- Beta 0.36, yield 0.9%, current ratio 1.24x
- 20.2% revenue growth vs GPAT's -100.0%
PSFE is the clearest fit if your priority is value.
- Lower P/E (3.3x vs 25.3x)
In this particular matchup, UPC is outpaced on most metrics by others in the set.
JPM is the clearest fit if your priority is long-term compounding.
- 465.8% 10Y total return vs HCI's 491.7%
- +21.8% vs PSFE's -45.0%
KO is the #2 pick in this set and the best alternative if income & stability is your priority.
- Dividend streak 56 yrs, beta -0.20, yield 2.5%
- 2.5% yield, 56-year raise streak, vs JPM's 1.9%, (4 stocks pay no dividend)
- 13.1% ROA vs UPC's -18.6%, ROIC 15.8% vs -7.8%
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | 20.2% revenue growth vs GPAT's -100.0% | |
| Value | Lower P/E (3.3x vs 25.3x) | |
| Quality / Margins | 32.6% margin vs UPC's -30.3% | |
| Stability / Safety | Beta 0.10 vs PSFE's 2.44, lower leverage | |
| Dividends | 2.5% yield, 56-year raise streak, vs JPM's 1.9%, (4 stocks pay no dividend) | |
| Momentum (1Y) | +21.8% vs PSFE's -45.0% | |
| Efficiency (ROA) | 13.1% ROA vs UPC's -18.6%, ROIC 15.8% vs -7.8% |
GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO — Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Segment breakdown not available.
Segment breakdown not available.
Segment breakdown not available.
GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO — Financial Metrics
Side-by-side numbers across 7 stocks — who leads on profitability, valuation, growth, and risk.
Who Leads Where
HCI leads in 3 of 6 categories
KO leads 2 • PSFE leads 1 • GPAT leads 0 • ACIC leads 0 • UPC leads 0 • JPM leads 0
Explore the data ↓Income & Cash Flow (Last 12 Months)
HCI leads this category, winning 3 of 6 comparable metrics.
Income & Cash Flow (Last 12 Months)
JPM and GPAT operate at a comparable scale, with $280.3B and $0 in trailing revenue. HCI is the more profitable business, keeping 32.6% of every revenue dollar as net income compared to UPC's -30.3%. On growth, KO holds the edge at +12.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| RevenueTrailing 12 months | $0 | $335M | $927M | $1.7B | $41M | $280.3B | $49.3B |
| EBITDAEarnings before interest/tax | -$551,918 | $154M | $454M | $373M | -$10M | $81.4B | $15.5B |
| Net IncomeAfter-tax profit | $12M | $107M | $303M | -$199M | -$12M | $57.0B | $13.7B |
| Free Cash FlowCash after capex | -$372,225 | $71M | $282M | $174M | -$15M | $100.9B | $12.6B |
| Gross MarginGross profit ÷ Revenue | — | +63.8% | +66.5% | +48.4% | +30.3% | +60.0% | +61.7% |
| Operating MarginEBIT ÷ Revenue | — | +42.6% | +47.9% | +5.5% | -26.7% | +25.9% | +29.3% |
| Net MarginNet income ÷ Revenue | — | +31.9% | +32.6% | -11.4% | -30.3% | +20.4% | +27.8% |
| FCF MarginFCF ÷ Revenue | — | +21.1% | +30.4% | +10.0% | -37.2% | +36.0% | +25.5% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | +9.3% | +11.9% | +10.4% | -14.1% | — | +12.1% |
| EPS Growth (YoY)Latest quarter vs prior year | -10.0% | +4.3% | +23.4% | -115.2% | -100.1% | +16.0% | +18.2% |
Valuation Metrics
PSFE leads this category, winning 3 of 7 comparable metrics.
Valuation Metrics
At 4.9x trailing earnings, ACIC trades at a 82% valuation discount to KO's 27.2x P/E. Adjusting for growth (PEG ratio), HCI offers better value at 0.13x vs KO's 2.43x — a lower PEG means you pay less per unit of expected earnings growth.
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| Market CapShares × price | $390M | $505M | $2.1B | $367M | $2M | $896.0B | $355.6B |
| Enterprise ValueMkt cap + debt − cash | $390M | $459M | $942M | $1.7B | -$23M | $1.50T | $390.8B |
| Trailing P/EPrice ÷ TTM EPS | 26.44x | 4.86x | 6.45x | -2.26x | -0.00x | 16.00x | 27.18x |
| Forward P/EPrice ÷ next-FY EPS est. | — | 10.94x | 9.26x | 3.27x | — | 14.40x | 25.27x |
| PEG RatioP/E ÷ EPS growth rate | — | — | 0.13x | — | — | 0.90x | 2.43x |
| EV / EBITDAEnterprise value multiple | — | 2.81x | 2.14x | 4.24x | — | 18.36x | 26.39x |
| Price / SalesMarket cap ÷ Revenue | — | 1.51x | 2.31x | 0.22x | 0.10x | 3.20x | 7.42x |
| Price / BookPrice ÷ Book value/share | 1.06x | 1.64x | 1.85x | 0.63x | 0.00x | 2.47x | 10.40x |
| Price / FCFMarket cap ÷ FCF | — | 7.13x | 4.69x | 1.64x | — | 8.88x | 67.15x |
Profitability & Efficiency
HCI leads this category, winning 5 of 9 comparable metrics.
Profitability & Efficiency
KO delivers a 41.1% return on equity — every $100 of shareholder capital generates $41 in annual profit, vs $-29 for PSFE. GPAT carries lower financial leverage with a 0.00x debt-to-equity ratio, signaling a more conservative balance sheet compared to PSFE's 4.06x. On the Piotroski fundamental quality scale (0–9), HCI scores 8/9 vs GPAT's 2/9, reflecting strong financial health.
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| ROE (TTM)Return on equity | +4.1% | +35.7% | +30.8% | -28.6% | -27.0% | +15.9% | +41.1% |
| ROA (TTM)Return on assets | +3.9% | +9.0% | +12.7% | -4.2% | -18.6% | +1.3% | +13.1% |
| ROICReturn on invested capital | -0.1% | +41.0% | +6.8% | +3.6% | -7.8% | +4.5% | +15.8% |
| ROCEReturn on capital employed | -0.2% | +26.0% | +40.6% | +3.6% | -5.6% | +8.9% | +17.3% |
| Piotroski ScoreFundamental quality 0–9 | 2 | 6 | 8 | 4 | 4 | 5 | 7 |
| Debt / EquityFinancial leverage | 0.00x | 0.48x | 0.06x | 4.06x | 0.16x | 2.60x | 1.33x |
| Net DebtTotal debt minus cash | $287,340 | -$46M | -$1.1B | $1.3B | -$24M | $599.0B | $35.2B |
| Cash & Equiv.Liquid assets | $112,660 | $199M | $1.2B | $1.3B | $34M | $343.3B | $10.3B |
| Total DebtShort + long-term debt | $400,000 | $152M | $68M | $2.7B | $9M | $942.4B | $45.5B |
| Interest CoverageEBIT ÷ Interest expense | — | 14.20x | 67.37x | 0.75x | -22.11x | 0.74x | 10.70x |
Total Returns (Dividends Reinvested)
HCI leads this category, winning 3 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in JPM five years ago would be worth $21,820 today (with dividends reinvested), compared to $3 for UPC. Over the past 12 months, JPM leads with a +21.8% total return vs PSFE's -45.0%. The 3-year compound annual growth rate (CAGR) favors HCI at 42.8% vs UPC's -90.1% — a key indicator of consistent wealth creation.
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| YTD ReturnYear-to-date | +1.6% | -1.6% | -12.3% | -11.0% | -22.1% | -0.5% | +20.3% |
| 1-Year ReturnPast 12 months | +2.4% | +5.2% | +2.0% | -45.0% | -16.7% | +21.8% | +17.2% |
| 3-Year ReturnCumulative with dividends | +8.5% | +137.8% | +191.2% | -33.0% | -99.9% | +138.2% | +47.0% |
| 5-Year ReturnCumulative with dividends | +8.5% | +98.7% | +83.5% | -94.9% | -100.0% | +118.2% | +65.6% |
| 10-Year ReturnCumulative with dividends | +8.5% | -24.1% | +491.7% | -94.1% | -100.0% | +465.8% | +121.1% |
| CAGR (3Y)Annualised 3-year return | +2.8% | +33.5% | +42.8% | -12.5% | -90.1% | +33.6% | +13.7% |
Risk & Volatility
KO leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
KO is the less volatile stock with a -0.20 beta — it tends to amplify market swings less than PSFE's 2.44 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. KO currently trades 98.3% from its 52-week high vs UPC's 29.5% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | -0.02x | 0.10x | 0.36x | 2.44x | 0.94x | 0.94x | -0.20x |
| 52-Week HighHighest price in past year | $12.00 | $13.06 | $210.50 | $15.02 | $11.00 | $337.25 | $84.04 |
| 52-Week LowLowest price in past year | $10.42 | $9.79 | $136.37 | $5.95 | $2.00 | $262.71 | $65.35 |
| % of 52W HighCurrent price vs 52-week peak | +90.3% | +80.0% | +76.2% | +47.3% | +29.5% | +95.1% | +98.3% |
| RSI (14)Momentum oscillator 0–100 | 61.8 | 44.8 | 61.4 | 39.7 | 52.5 | 59.1 | 60.6 |
| Avg Volume (50D)Average daily shares traded | 120K | 238K | 180K | 324K | 24K | 7.0M | 12.7M |
Analyst Outlook
KO leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Analyst consensus: ACIC as "Hold", HCI as "Buy", PSFE as "Buy", JPM as "Buy", KO as "Buy". Consensus price targets imply 42.7% upside for PSFE (target: $10) vs -81.8% for ACIC (target: $2). For income investors, KO offers the higher dividend yield at 2.46% vs HCI's 0.93%.
| Metric | |||||||
|---|---|---|---|---|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | Hold | Buy | Buy | — | Buy | Buy |
| Price TargetConsensus 12-month target | — | $1.90 | $126.50 | $10.13 | — | $339.75 | $86.13 |
| # AnalystsCovering analysts | — | 5 | 14 | 11 | — | 61 | 48 |
| Dividend YieldAnnual dividend ÷ price | — | — | +0.9% | — | — | +1.9% | +2.5% |
| Dividend StreakConsecutive years of raises | — | 0 | 0 | — | 2 | 15 | 56 |
| Dividend / ShareAnnual DPS | — | — | $1.50 | — | — | $5.95 | $2.04 |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% | +0.1% | +27.6% | 0.0% | +3.9% | +0.2% |
HCI leads in 3 of 6 categories (Income & Cash Flow, Profitability & Efficiency). KO leads in 2 (Risk & Volatility, Analyst Outlook).
GPAT vs ACIC vs HCI vs PSFE vs UPC vs JPM vs KO: Key Questions Answered
10 questions · data-driven answers · updated daily
01Is GPAT or ACIC or HCI or PSFE or UPC or JPM or KO a better buy right now?
For growth investors, HCI Group, Inc.
(HCI) is the stronger pick with 20. 2% revenue growth year-over-year, versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). American Coastal Insurance Corporation (ACIC) offers the better valuation at 4. 9x trailing P/E (10. 9x forward), making it the more compelling value choice. Analysts rate HCI Group, Inc. (HCI) a "Buy" — based on 14 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which has the better valuation — GPAT or ACIC or HCI or PSFE or UPC or JPM or KO?
On trailing P/E, American Coastal Insurance Corporation (ACIC) is the cheapest at 4.
9x versus The Coca-Cola Company at 27. 2x. On forward P/E, Paysafe Limited is actually cheaper at 3. 3x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: HCI Group, Inc. wins at 0. 19x versus The Coca-Cola Company's 2. 26x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.
03Which is the better long-term investment — GPAT or ACIC or HCI or PSFE or UPC or JPM or KO?
Over the past 5 years, JPMorgan Chase & Co.
(JPM) delivered a total return of +118. 2%, compared to -100. 0% for Universe Pharmaceuticals Inc. (UPC). Over 10 years, the gap is even starker: HCI returned +491. 7% versus UPC's -100. 0%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
04Which is safer — GPAT or ACIC or HCI or PSFE or UPC or JPM or KO?
By beta (market sensitivity over 5 years), The Coca-Cola Company (KO) is the lower-risk stock at -0.
20β versus Paysafe Limited's 2. 44β — meaning PSFE is approximately -1317% more volatile than KO relative to the S&P 500. On balance sheet safety, GP-Act III Acquisition Corp. (GPAT) carries a lower debt/equity ratio of 0% versus 4% for Paysafe Limited — giving it more financial flexibility in a downturn.
05Which is growing faster — GPAT or ACIC or HCI or PSFE or UPC or JPM or KO?
By revenue growth (latest reported year), HCI Group, Inc.
(HCI) is pulling ahead at 20. 2% versus -22. 4% for Universe Pharmaceuticals Inc. (UPC). On earnings-per-share growth, the picture is similar: HCI Group, Inc. grew EPS 179. 8% year-over-year, compared to -972. 2% for Paysafe Limited. Over a 3-year CAGR, HCI leads at 22. 3% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.
06Which has better profit margins — GPAT or ACIC or HCI or PSFE or UPC or JPM or KO?
HCI Group, Inc.
(HCI) is the more profitable company, earning 33. 2% net margin versus -20. 6% for Universe Pharmaceuticals Inc. — meaning it keeps 33. 2% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: HCI leads at 47. 7% versus -16. 3% for UPC. At the gross margin level — before operating expenses — ACIC leads at 86. 3%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
07Is GPAT or ACIC or HCI or PSFE or UPC or JPM or KO more undervalued right now?
The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.
By this metric, HCI Group, Inc. (HCI) is the more undervalued stock at a PEG of 0. 19x versus The Coca-Cola Company's 2. 26x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Paysafe Limited (PSFE) trades at 3. 3x forward P/E versus 25. 3x for The Coca-Cola Company — 22. 0x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for PSFE: 42. 7% to $10. 13.
08Which pays a better dividend — GPAT or ACIC or HCI or PSFE or UPC or JPM or KO?
In this comparison, KO (2.
5% yield), JPM (1. 9% yield), HCI (0. 9% yield) pay a dividend. GPAT, ACIC, PSFE, UPC do not pay a meaningful dividend and should not be held primarily for income.
09Is GPAT or ACIC or HCI or PSFE or UPC or JPM or KO better for a retirement portfolio?
For long-horizon retirement investors, The Coca-Cola Company (KO) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β -0.
20), 2. 5% yield, +121. 1% 10Y return). Paysafe Limited (PSFE) carries a higher beta of 2. 44 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (KO: +121. 1%, PSFE: -94. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
10What are the main differences between GPAT and ACIC and HCI and PSFE and UPC and JPM and KO?
These companies operate in different sectors (GPAT (Financial Services) and ACIC (Financial Services) and HCI (Financial Services) and PSFE (Technology) and UPC (Healthcare) and JPM (Financial Services) and KO (Consumer Defensive)), which means they face different economic cycles, regulatory environments, and macro sensitivities — making direct comparison nuanced.
In terms of investment character: GPAT is a small-cap quality compounder stock; ACIC is a small-cap deep-value stock; HCI is a small-cap high-growth stock; PSFE is a small-cap quality compounder stock; UPC is a small-cap quality compounder stock; JPM is a large-cap deep-value stock; KO is a large-cap quality compounder stock. HCI, JPM, KO pay a dividend while GPAT, ACIC, PSFE, UPC do not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.